25

20

30

1. A method for modulating a disease or condition associated with phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising

administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula

$$Q_4H$$
 Q_4H
 Q_4H

wherein X is R_1 , OR_1 , or SR_1 ;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;


(vi) substituted phenyl

$$Z_{i}$$
 Z_{ii}
 Z_{iii}
 Z_{iv}

wherein Z_i , Z_{ii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN,

30

wherein R₅ is



IM

20

₌ 15

wherein Z_i , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

- (a) H;
- (b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated polymorphoneutrophil (PMN) inflammation in a subject is modulated.

- 2. The method of claim 1, wherein said method is performed in vitro.
- 3. The method of claim 1, wherein said method is performed in vivo.

25

administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula

5

TO THE INTERIOR WAS THE wherein X is R_1 , OR_1 , or SR_1 ;

wherein R_1 is

a hydrogen atom; (i)

(ii) an alkylof 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

 Z_{iii}

a cycloalkyl of 3 to 10 carbon atoms; (iii)

an aralkyl of 7 to 12 carbon atoms; (iv)

phenyl; (v)

substituted phenyl (vi)

25

ROLLOGI

20

30

wherein Z_i , Z_{ii} , Z_{iv} and Z_v are each independently selected from -NO₂, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to

25

20

8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or/

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=0), SO₂ or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O, S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is

- (a) H;
- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
- (e) $R_aQ_2R_b$ wherein Q_2 is Q or -S-; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R₄ is

- (a) /H
- (b) / an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein/R₅ is

wherein Z_i , Z_{ii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

20

The first first first first first

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that PLD initiated polymorphoreutrophil (PMN) inflammation is treated in a subject.

25

- 5. The/method of claim 1, wherein said method is performed in vitro.
- 6. The method of claim 1, wherein said method is performed in vivo.

7. A method for modulating a disease or condition associated with phosphlipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising

administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula

$$Q_4H$$
 Q_3H
 Q_3H
 Q_1
 Q_1
 Q_1
 Q_2
 Q_3
 Q_4
 Q

wherein X is R_1 , OR_1 , or SR_1 ; wherein R_1 is

- (i) a hydrogen atom;
- (ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;
- (iii) a cycloalkyl of 3 to 10 carbon atoms;
- (iv) an aralkyl of 7 to 12 carbon atoms;
- (v) phenyl;
- (vi) / substituted phenyl

 Z_{i} Z_{ii} Z_{iii} Z_{iii}

wherein Z_{ii} , Z_{ii} , Z_{iv} and Z_{v} are each independently selected from -NO₂, -CN,

5

20

25

(vii)

a detectable label molecule; or

(viii)

a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=0), SO_2 or (CN), provided when Q_1 is CN, then X is absent; wherein Q₃ and Q₄ are each independently O, S or NH; wherein one of R₂ and R₃ is a hydrogen atom and the other is

(a) H;

- (b) an alkyl of 1 to 8/carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalkyl of 3/to 6/carbon atoms, inclusive;
- an alkenyl of 2/to 8/carbon atoms, inclusive, which may be straight (d) chain or branched; or
- $R_aQ_2R_y$ wherein Q_2 is -O- or -S-; wherein R_a is alkylene of 0 to 6 (e) carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R₄

(a/)

H;

an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

herein R₅ is

20

5

THE LESS OF THE STREET

₌ 15

Ļå

ļ.

į O

25

 Z_{i} Z_{ii} Z_{iii}

5

wherein Z_i , Z_{ii} , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

20

- (a) H;
- (b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated superoxide generation or degranulation activity in a subject is modulated.

- 8. The method of claim 7, wherein said method is performed in vitro.
- 9. The method of claim 7, wherein said method is performed in vivo.

10. A method for treating phospholipase D (PLD) initiated superoxide generation or degranulation in a subject, comprising

administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula

 Q_4H Q_3H Q_3H Q_1 Q_1 Q_1 Q_2 Q_3 Q_4 Q_4 Q_5 Q_5 Q

wherein X is R_1 , OR_1 , or SR_1 ; wherein R_1 is

(i) a hydrogen atom;

(ii) an alkylof 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) /substituted phenyl

 Z_{i} Z_{ii} Z_{iii} Z_{iii}

wherein Z_i , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_i$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to

10

5

of the state of the state of

. 20

≡ 15

25

<u>1</u>0

8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O, S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
- (e) $R_aQ_2R_b$ wherein Q_2 is -0 or -S; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;


wherein R₄ is

(a) 1/1

(b) / an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is

25



≢ 15

١D,

20

wherein Z_i , Z_{iii} , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

(a) H;

(b) an alkyl/from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or \$, and pharmaceutically acceptable salts thereof, such that PLD initiated superoxide generation or granulation is treated in a subject.

25

- 11. The method of claim 10, wherein said method is performed in vitro.
- 12. The method of claim 10, wherein said method is performed in vivo.

30

13. A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated activity in a subject, comprising:

wherein R_1 is


a container holding a therapeutically effective amount of at least one lipoxin compound having the formula

5

25

20

30



(i) a hydrogen/atom;


(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralky/of 7, to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i , Z_{ii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and

(vii)

a detectable label molecule; or

(viii)

a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=0), SO_2 or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O, S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is

- (a) H;
- (b) an alkyl of 1 to/8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalky/ of 3 to/6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
- (e) $R_aQ_2R_b$ wherein Q_2 is -O- or -S-; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R₄ i


У Н;

an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

5

20

wherein R₅ is



wherein Z_i , Z_{ii} , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsybstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated activity in the subject.

5

20

14. A packaged pharmaceutical composition for treating phospholipase D initiated activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula


 Q_4H Q_3H Q_3H Q_1 Q_1 Q_1 Q_2 Q_3 Q_4 Q_4 Q

wherein X is R_1 , OR_1 , or SR_1 ; wherein R_1 is

- (i) a hydrogen afom;
- (ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain on branched;

77

- (iii) a cycloalkyl of 3 to 10 carbon atoms;
- (iv) an aralkyl of 7 to 12 carbon atoms;
- (v) phenyl;
- (vi) substituted phenyl



wherein Z_i , Z_{ii} , Z_{iv} and Z_v are each independently selected from -NO₂, -CN, -C(=O)-R₁, -SO₃H, a hydrogen atom, halogen, methyl, -OR_x, wherein R_x is 1 to

5

20

25

(vii) a detectable label molecule; for

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O, S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is

- (a) H;
- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched.
- (c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
- (e) $R_aQ_2R_b$ wherein Q_2 is O- or -S-; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R4 is

(a) / H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R₅ is

10 غــة

5

20

25

<u>}</u>₌410

Sill first that the first than the

20

wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from -NO₂, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y₁ is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an allowy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0/to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

(a)

H;

an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or (b) branched;

25

wherein T is O or S, and pharmaceutically acceptable salts thereof; and instructions for using said lipoxin compound for treating PLD initiated activity in the subject.

A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising:

30

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula

The state of the s

25

20

30

$$Q_4H$$

$$Q_3H$$

$$R_4$$

$$R_5$$

$$R_3$$

$$R_6$$

$$Y_1$$

$$R_1$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_3$$

$$R_4$$

$$R_5$$

$$R_3$$

$$R_3$$

$$R_4$$

$$R_5$$

$$R_3$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_3$$

$$R_4$$

$$R_5$$

$$R_3$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_5$$

$$R_3$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_3$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_3$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_3$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_5$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_5$$

$$R_3$$

$$R_4$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_1$$

$$R_2$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_5$$

$$R_5$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_1$$

$$R_2$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_5$$

$$R_5$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_1$$

$$R_2$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_5$$

$$R_5$$

$$R_6$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_1$$

$$R_2$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_5$$

$$R_5$$

$$R_6$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_1$$

$$R_2$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_4$$

$$R_5$$

$$R_5$$

$$R_6$$

$$R_6$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_4$$

$$R_4$$

$$R_5$$

$$R_6$$

$$R_6$$

$$R_1$$

$$R_2$$

$$R_1$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_4$$

$$R_4$$

$$R_5$$

$$R_$$

(i) a hydrogen atom;


(ii) an alkyl of 1/to 8 carbons atoms, inclusive, which may be straight/chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an arallyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(viii) a

(vii) a detectable label molecule; or

a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=0), SO_2 or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O, S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is


- (a) H;
- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
- (e) $R_aQ_2R_b$ wherein Q_2 is -Q- or -S=; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R₄ is

- (a) H;
- (b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

25

wherein R₅ is



wherein Z_i , Z_{ii} , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R₆ is

(a) H

(b) /an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated superoxide generation or degranulation activity in the subject.

5

20

16. A packaged pharmaceutical composition for treating phospholipase D

(PLD) initiated superoxide generation or degranulation activity in a subject, comprising:
a container holding a therapeutically effective amount of at least one lipoxin
compound having the formula

 Q_4H Q_3H Q_3H Q_1 Q_1 Q_1 Q_2 Q_3 Q_4 Q_4 Q

wherein X is R_1 , OR_1 , or SR_1 ; wherein R_1 is

(iv)

(i) a hydrogen arom;


(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) / a cycloalkyl of 3 to 10 carbon atoms;

/ an aralkyl of 7 to 12 carbon atoms;

(v) / phenyl;

(vi) substituted phenyl



wherein Z_i , Z_{ii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN,

5

20

25

 $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule, or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent; wherein Q_3 and Q_4 are each independently O, S or NH; wherein one of R_2 and R_3 is a hydrogen atom and the other is

- (a) H;
- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalky/of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched, or
- (e) $R_aQ_2R_b$ wherein Q_2 is -O- or -S-; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R₄/is

(a) H;

/(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R₅ is


25

20

£ 15

20

25



wherein Z_i , Z_{ii} , Z_{iii} , Z_{iv} and Z_v are each independently selected from $-NO_2$, -CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z_b is cyano, nitro or a halogen;

wherein R₆ is

- (a) H;
- (b) an alky from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O of S, and pharmaceutically acceptable salts thereof; and instructions for using said lipoxin compound for treating PLD initiated superoxide generation or degranulation activity in the subject.